UBS analyst Manav Gupta maintained a 'Neutral' rating on Calumet (CLMT) but significantly raised its price target from $26 to $47. This indicates a more optimistic outlook on the company's future valuation by UBS, despite not upgrading the overall recommendation.
UBS analyst Manav Gupta maintained a 'Neutral' rating on Calumet (CLMT) but substantially increased the price target from $26 to $47. This action suggests that while UBS doesn't see an immediate 'buy' opportunity, they believe the stock has significantly more upside potential than previously thought. This could lead to a short-term positive reaction in CLMT's stock price as investors react to the higher valuation. For traders, this presents an opportunity to consider the stock, although the 'Neutral' rating implies that the analyst still sees some balanced risks or limited immediate catalysts for a strong upward move.